uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
KIT signaling is dispensable for human mast cell progenitor development
Karolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden..
Karolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden..
Karolinska Univ Hosp, Karolinska Inst, Dept Med, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular tools. Uppsala University, Science for Life Laboratory, SciLifeLab.
Show others and affiliations
2017 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 130, no 16, p. 1785-1794Article in journal (Refereed) Published
Abstract [en]

Human hematopoietic progenitors are generally assumed to require stem cell factor (SCF) and KIT signaling during differentiation for the formation of mast cells. Imatinib treatment, which inhibits KIT signaling, depletes mast cells in vivo. Furthermore, the absence of SCF or imatinib treatment prevents progenitors from developing into mast cells in vitro. However, these observations do not mean that mast cell progenitors require SCF and KIT signaling throughout differentiation. Here, we demonstrate that circulating mast cell progenitors are present in patients undergoing imatinib treatment. In addition, we show that mast cell progenitors from peripheral blood survive, mature, and proliferate without SCF and KIT signaling in vitro. Contrary to the prevailing consensus, our results show that SCF and KIT signaling are dispensable for early mast cell development.

Place, publisher, year, edition, pages
2017. Vol. 130, no 16, p. 1785-1794
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-339750DOI: 10.1182/blood-2017-03-773374ISI: 000413246200005PubMedID: 28790106OAI: oai:DiVA.org:uu-339750DiVA, id: diva2:1177537
Funder
Swedish Research CouncilSwedish Cancer SocietyCancer and Allergy FoundationThe Cancer Society in StockholmThe Cancer Research Funds of RadiumhemmetThe Karolinska Institutet's Research FoundationAvailable from: 2018-01-25 Created: 2018-01-25 Last updated: 2018-01-25Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Löf, LizaAmini, Rose-MarieHagberg, HansOlsson-Strömberg, UllaNilsson, Gunnar

Search in DiVA

By author/editor
Löf, LizaAmini, Rose-MarieHagberg, HansOlsson-Strömberg, UllaNilsson, Gunnar
By organisation
Molecular toolsScience for Life Laboratory, SciLifeLabClinical and experimental pathologyExperimental and Clinical OncologyHaematology
In the same journal
Blood
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf